NCCN Guidelines for Patients® | Chronic Myelogenous Leukemia - page 26

NCCN Guidelines for Patients
: Chronic Myelogenous Leukemia
Version 1.2014
1.1 What are blood cells?
3 5 Tools
American Cancer Society
European LeukemiaNet
Leukemia and Lymphoma Society
National Cancer Institute
National Marrow Donor Program
• CML is divided into three groups (phases) of progression.
• The phase of CML is based on the number of immature white blood cells, called blasts, in
the peripheral blood and bone marrow.
• Prognostic scoring systems use certain factors to help predict the likely outcome
(prognosis) and guide treatment decisions.
Review of Part 3
1...,16,17,18,19,20,21,22,23,24,25 27,28,29,30,31,32,33,34,35,36,...100
Powered by FlippingBook